Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

Study Evaluating 2 Dosing Regimens Of TRU-015 In Rheumatoid Arthritis

ClinicalTrials.gov ID: NCT00634933

Public ClinicalTrials.gov record NCT00634933. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 4, 2026, 2:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Parallel, Double-Blind, Placebo-Controlled Dose Regimen Finding Study To Evaluate The Safety And Efficacy Of TRU-015 In Subjects With Active Seropositive Rheumatoid Arthritis On A Stable Background Of Methotrexate

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will evaluate the efficacy and safety of two dosing regimens of a compound known as TRU-015 in combination with methotrexate (MTX) in patients with active rheumatoid arthritis.

Study identification

NCT ID
NCT00634933
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Pfizer
Industry
Enrollment
222 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 29, 2008
Primary completion
Jan 31, 2010
Completion
Sep 30, 2012
Last update posted
Mar 10, 2013

2008 – 2012

United States locations

U.S. sites
29
U.S. states
17
U.S. cities
27
Facility City State ZIP Site status
Pfizer Investigational Site Birmingham Alabama 35294-7201
Pfizer Investigational Site Paradise Valley Arizona 85253
Pfizer Investigational Site Los Angeles California 90048
Pfizer Investigational Site Los Angeles California 90095
Pfizer Investigational Site Santa Maria California 93454-6945
Pfizer Investigational Site Santa Monica California 90404
Pfizer Investigational Site Daytona Beach Florida 32117
Pfizer Investigational Site Ocala Florida 34474
Pfizer Investigational Site Palm Harbor Florida 34684
Pfizer Investigational Site Chicago Illinois 60612
Pfizer Investigational Site Springfield Illinois 62704
Pfizer Investigational Site Worcester Massachusetts 01605
Pfizer Investigational Site Worcester Massachusetts 01608
Pfizer Investigational Site Grande Rapids Michigan 49546
Pfizer Investigational Site Flowood Mississippi 39232
Pfizer Investigational Site St Louis Missouri 63110
Pfizer Investigational Site Syracuse New York 13210
Pfizer Investigational Site Charlotte North Carolina 28210
Pfizer Investigational Site Minot North Dakota 58701
Pfizer Investigational Site Cincinnati Ohio 45245
Pfizer Investigational Site Mayfield Village Ohio 44143
Pfizer Investigational Site Oklahoma City Oklahoma 73112
Pfizer Investigational Site Danville Pennsylvania 17822
Pfizer Investigational Site State College Pennsylvania 16801
Pfizer Investigational Site Wexford Pennsylvania 15090
Pfizer Investigational Site Wilkes-Barre Pennsylvania 18711-3762
Pfizer Investigational Site Dallas Texas 75231
Pfizer Investigational Site San Antonio Texas 78232
Pfizer Investigational Site Clarksburg West Virginia 26301

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 36 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00634933, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 10, 2013 · Synced Sep 4, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00634933 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →